Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2004

View Archived Issues

Therapeutic benefits of recombinant PSA vaccines in advanced prostate cancer

Pulmicort HFA-MDI completes phase III

CDC recommends resumption of third Prevnar dose

Positive data, revised phase III plans for naveglitazar

BresaGen completes U.S. merger with Cythera

Positive phase II results for Allox

Abbott plans Xinlay NDA filing later this year

New phase II trial for M-40403

Enrollment begins in phase II Xcytrin study for metastatic renal cell carcinoma

Second subgroup in Sinovac SARS vaccine phase I trials receives inoculations

MS-325 in new post-NDA program

Phase IIb study evaluates Reverset in HIV patients failing therapy

Tacrolimus results presented at pediatric dermatology congress

Novel insulin-like growth factor-I receptor kinase inhibitors against tumor growth

Zafirlukast induces symptomatic response in women with recurrent VVC

Clinical evidence for the efficacy of pregabalin in painful diabetic neuropathy

Salbutamol reported to improve muscle strength in children with congenital myopathies

Benzoxazinone derivatives for the treatment of CNS and other disorders

Selective angiotensin AT2 receptor agonists described by Vicore Pharma

Nonsteroidal modulators of farnesoid X receptors described in patent literature

Takeda patent claims compounds that inhibit somatostatin receptor binding

Inhibitors of receptor tyrosine kinases claimed by Array BioPharma

CRF1 receptor antagonists for anxiety, affective disorders, etc.

Good safety and acceptability profile found with Carraguard in HIV-positive patients

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...